Aurinia Pharmaceuticals Inc.'s SEC filings document the formal reporting record for a Canada-incorporated biopharmaceutical company commercializing LUPKYNIS and developing autoimmune-disease therapies. 8-K filings furnish operating and financial results, product revenue, license, collaboration and royalty revenue, research and development spending, guidance-related exhibits and other material-event disclosures.
The filings also cover proxy governance, executive appointments and compensatory arrangements, shareholder voting matters, capital-structure disclosures, share repurchase activity and material agreements. Recent transaction records include completed acquisition activity, tender-offer and merger mechanics, and contingent value right terms.
Morgan Stanley Smith Barney LLC intends to sell 3,136,201 shares of Common Stock on 05/11/2026 via the exercise of options under a registered plan.
The filing shows an aggregate value of $49,677,423.84 and reports 128,601,671 shares outstanding as of 05/11/2026; the method of sale is listed as cash.
Proposed sale of common stock by a holder via Form 144. The filing lists 717,688 common shares associated with an exercise of options under a registered plan with an indicated trade date of 05/11/2026. The sales method is listed as cash.
Morgan Stanley Smith Barney LLC Executive Financial Services filed a notice to sell 500,503 shares of Common Stock on 05/11/2026 related to an exercise of options under a registered plan. The filing lists an aggregate value of $7,927,967.52 and identifies the exchange as NASDAQ.
Aurinia Pharmaceuticals Inc. completed its acquisition of Kezar Life Sciences through a tender offer and follow-on merger. Kezar stockholders received $6.955 in cash per share plus one contingent value right, with 5,927,580 shares tendered, representing about 80.24% of outstanding shares at expiration.
After the tender offer closed, Aurinia merged its subsidiary into Kezar under Delaware law, making Kezar a wholly owned subsidiary. In-the-money Kezar stock options became fully vested and were cashed out for the cash portion of the offer plus CVRs, while out-of-the-money options were cancelled with no payment. Kezar’s employee stock purchase plan was terminated immediately before the merger became effective.
Aurinia Pharmaceuticals delivered a stronger Q1 2026, driven by growth in its lupus nephritis drug LUPKYNIS. Total revenue rose to $77.7 million from $62.5 million, as net product sales increased 23% to $73.6 million and collaboration revenue with Otsuka also expanded.
Net income improved to $34.4 million from $23.3 million, with gross margin rising to 92% from 86% as lower low-margin sales to Otsuka reduced cost of revenue. Operating cash flow surged to $32.6 million, up from $1.3 million, reflecting higher profitability and working-capital shifts.
Aurinia ended the quarter with $378.8 million in cash, equivalents, restricted cash and investments, even after repurchasing 2.5 million shares for $36.8 million; cumulative buybacks since February 2024 total 23.1 million shares for $211.0 million. The company signed a definitive agreement to acquire Kezar Life Sciences for $6.955 per share in cash plus a contingent value right, targeting additional autoimmune and oncology assets. Leadership also changed, with Kevin Tang appointed CEO, Ryan Cole COO and Michael Hearne CFO, replacing the prior executive team, which remains as consultants during a transition period.
Aurinia Pharmaceuticals reported strong results for the three months ended March 31, 2026. Total revenue reached $77.7 million, up 24% from $62.5 million a year earlier, driven mainly by LUPKYNIS net product sales of $73.6 million, up 23%.
Net income was $34.4 million, a 48% increase from $23.3 million, with diluted earnings per share rising to $0.25 from $0.16. Operating cash flow improved sharply to $32.6 million from $1.3 million, while cash, cash equivalents, restricted cash and investments totaled $378.8 million as of March 31, 2026.
The company repurchased 2.5 million common shares for $36.2 million during the quarter and reaffirmed 2026 guidance, targeting total revenue of $315–$325 million and LUPKYNIS net product sales of $305–$315 million.
Aurinia Pharmaceuticals Inc. is holding its 2026 annual general meeting virtually on June 3, 2026, asking shareholders to elect five directors, approve PricewaterhouseCoopers LLP as auditor, and give a non-binding say-on-pay vote. Shareholders of record on April 14, 2026, when 129,938,324 common shares were outstanding, may vote.
The proxy outlines an 80% independent board, a lead independent director, and fully independent audit, compensation and governance committees. PwC billed $904,141 in total fees for 2025. The company reports 2025 executive pay decisions, a 150% payout under the annual bonus plan, and a shift toward performance-based stock options and PSUs, while new CEO Kevin Tang has elected to receive no compensation in 2026 and the COO and CFO each have $300,000 base salaries with 50% target bonuses.
Aurinia Pharmaceuticals Inc. plans to acquire Kezar Life Sciences through a tender offer at $6.955 in cash per share plus one non-transferable contingent value right (CVR) for each Kezar share. After the offer, a follow-on merger will make Kezar a wholly owned Aurinia subsidiary under Delaware’s Section 251(h) process.
The CVR will give Kezar stockholders potential additional cash tied to Kezar’s closing net cash above $50.0 million, proceeds from existing Enodia and Everest agreements, and future monetization or development of zetomipzomib and other legacy assets over up to 10 years. A key Kezar holder owning about 9.0% of the stock has agreed to tender its shares, and closing is targeted for the second quarter of 2026, subject to minimum tender, net cash and other customary conditions.
Aurinia Pharmaceuticals Inc. disclosed that Chief Operating Officer Ryan Cole filed an initial statement of beneficial ownership on Form 3. This filing formally registers him as a reporting person for the company’s equity under securities regulations and establishes the baseline for any future insider transaction reports.
Aurinia Pharmaceuticals Inc. disclosed that Michael S. Hearne, its Chief Financial Officer, filed an initial Form 3 as a reporting person. This filing establishes his insider status for future ownership and transaction reporting but does not list any specific share holdings or recent trades.